![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Dramatic progress is being made in the identification of genes that are involved in oncogenesis and cancer progression. Novel therapeutic oligonucleotides, such as those that can block the expression of specific target genes (antisense) and those that can interfere with a specific enhancer element-directed transcription in vivo (triple helix-forming or decoy), are potentially powerful tools for the therapeutic manipulation of genes associated with cancer. Such a gene-targeting approach is no longer a wishful dream, but a reality that will drive clinical medicine in the foreseeable future.